“Parkinsons disease (PD) is a neurodegenerative disorder that affects approximately 1.5% of the global population over age 65. Current therapeutic interventions for PD are typically limited to attempts to correct the depletion of dopamine once motor symptoms become moderate to severe. Interventions with the potential to improve the cognitive function and quality of life of […]
Read More